Company’s 36-month beta value is 0.92.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BCYC is 65.57M, and currently, short sellers hold a 6.52% ratio of that floaft. The average trading volume of BCYC on January 31, 2025 was 561.36K shares.
BCYC) stock’s latest price update
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC)’s stock price has gone rise by 3.60 in comparison to its previous close of 12.77, however, the company has experienced a 1.93% increase in its stock price over the last five trading days. businesswire.com reported 2025-01-13 that CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and.
BCYC’s Market Performance
BCYC’s stock has risen by 1.93% in the past week, with a monthly drop of -6.37% and a quarterly drop of -45.93%. The volatility ratio for the week is 4.91% while the volatility levels for the last 30 days are 5.94% for Bicycle Therapeutics Plc ADR The simple moving average for the past 20 days is -4.25% for BCYC’s stock, with a -38.40% simple moving average for the past 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Stephens repeating the rating for BCYC by listing it as a “Equal-Weight.” The predicted price for BCYC in the upcoming period, according to Stephens is $25 based on the research report published on November 08, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $35. The rating they have provided for BCYC stocks is “Outperform” according to the report published on September 06th, 2024.
B. Riley Securities gave a rating of “Neutral” to BCYC, setting the target price at $28 in the report published on August 07th of the previous year.
BCYC Trading at -18.99% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.85% of loss for the given period.
Volatility was left at 5.94%, however, over the last 30 days, the volatility rate increased by 4.91%, as shares sank -6.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.61% lower at present.
During the last 5 trading sessions, BCYC rose by +1.39%, which changed the moving average for the period of 200-days by -39.69% in comparison to the 20-day moving average, which settled at $13.81. In addition, Bicycle Therapeutics Plc ADR saw -5.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Thompson Travis Alvin, who sale 2,686 shares at the price of $15.00 back on Jan 06 ’25. After this action, Thompson Travis Alvin now owns 32,146 shares of Bicycle Therapeutics Plc ADR, valued at $40,290 using the latest closing price.
Thompson Travis Alvin, the CHIEF ACCOUNTING OFFICER of Bicycle Therapeutics Plc ADR, sale 1,750 shares at $14.09 during a trade that took place back on Jan 02 ’25, which means that Thompson Travis Alvin is holding 34,991 shares at $24,658 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.81 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -4.51. The total capital return value is set at -0.23. Equity return is now at value -26.82, with -20.45 for asset returns.
Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.28. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -87.93.
Currently, EBITDA for the company is -183.4 million with net debt to EBITDA at 4.85. When we switch over and look at the enterprise to sales, we see a ratio of 1.13. The receivables turnover for the company is 0.64for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.13.
Conclusion
In a nutshell, Bicycle Therapeutics Plc ADR (BCYC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
